SEOUL (Reuters) – South Korea’s Celtrian Inc. <068270.KS> Monday said it has received Emergency Use Author Theory (EUA) from the US Food and Drug Administration (FDA) for its rapid COVID-19 test kit completion, which has boosted shares of the company and its affiliates.
Celtrian said that sampinut delivers coronavirus test results within 10 minutes with a sensitivity of about 94%.
The approval came three months after a request for approval in late July, and the company said in a statement that the product was launched in the United States in August.
“(The company) is planning to supply Sampinut to the United States by local wholesalers, as it believes that demand for rapid diagnostic kits will be higher, mainly for large businesses and government agencies that are to return to work after telecommuting.” In a statement.
Shares of Celtrian Inc. rose 4..6%, while Celtrian firm <068760.KQ> And Celtrian Healthcare <091990.KQ> Increased by 6.6% and 1.6% respectively. Broder Co.SPI. <.KS11>However, it is trading 0.1% lower at 0208 GMT.
(Reporting by Jury Roh; Editing by Kim Kogil)
